From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease.
暂无分享,去创建一个
[1] E. Olson,et al. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. , 1999, Circulation research.
[2] M. Quiñones,et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. , 1995, Circulation.
[3] E. Kranias,et al. Phospholamban: a protein coming of age. , 1997, Biochemical and biophysical research communications.
[4] M. Webb-Peploe,et al. Echocardiographic left ventricular wall thickness: A poor predictor of the severity of aortic valve stenosis , 1991, Clinical cardiology.
[5] T. Hewett,et al. Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice. , 1998, The Journal of clinical investigation.
[6] P. Burch,et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. , 1999, Circulation.
[7] E. Maestrini,et al. A novel X-linked gene, G4.5. is responsible for Barth syndrome , 1996, Nature Genetics.
[8] T. Hewett,et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.
[9] H. Hidaka,et al. Demonstration of a Ca2+/calmodulin dependent protein kinase cascade in the hog heart. , 1998, Biochemical and biophysical research communications.
[10] G. King,et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[11] Frederick J. Schoen,et al. A Mouse Model of Familial Hypertrophic Cardiomyopathy , 1996, Science.
[12] K. Chien,et al. Stress Pathways and Heart Failure , 1999, Cell.
[13] H. Schulman,et al. The Nuclear δB Isoform of Ca2+/Calmodulin-dependent Protein Kinase II Regulates Atrial Natriuretic Factor Gene Expression in Ventricular Myocytes* , 1997, The Journal of Biological Chemistry.
[14] G. Fishman,et al. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. , 1997, The Journal of clinical investigation.
[15] I. Ohtsuki,et al. Ca2+ Sensitization and Potentiation of the Maximum Level of Myofibrillar ATPase Activity Caused by Mutations of Troponin T Found in Familial Hypertrophic Cardiomyopathy* , 1999, The Journal of Biological Chemistry.
[16] J. Seidman,et al. Mutations in the cardiac myosin binding protein–C gene on chromosome 11 cause familial hypertrophic cardiomyopathy , 1995, Nature Genetics.
[17] M. Gardner,et al. Localization of a gene responsible for arrhythmogenic right ventricular dysplasia to chromosome 3p23. , 1998, Circulation.
[18] M. Entman,et al. Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. , 1998, The Journal of clinical investigation.
[19] J. Seidman,et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.
[20] C. Balke,et al. Alterations in calcium handling in cardiac hypertrophy and heart failure. , 1998, Cardiovascular research.
[21] H. Hidaka,et al. Protein kinase C and calmodulin kinase are required for endothelin-stimulated atrial natriuretic factor secretion from primary atrial myocytes. , 1992, The Journal of biological chemistry.
[22] N. Dzimiri. Regulation of β-Adrenoceptor Signaling in Cardiac Function and Disease , 1999 .
[23] G. Danieli,et al. Arrhythmogenic right ventricular cardiomyopathy a still underrecognized clinic entity. , 1997, Trends in cardiovascular medicine.
[24] G. King,et al. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. , 1999, Circulation.
[25] J. Brown,et al. Rho as a mediator of G protein-coupled receptor signaling. , 1999, Molecular pharmacology.
[26] R. Doughty,et al. Beta-adrenergic blocking agents in the treatment of congestive heart failure: mechanisms and clinical results. , 1997, Annual review of medicine.
[27] S. Vatner,et al. Adverse Effects of Chronic Endogenous Sympathetic Drive Induced by Cardiac Gsα Overexpression , 1996 .
[28] S. Shenolikar,et al. Protein serine/threonine phosphatases--new avenues for cell regulation. , 1994, Annual review of cell biology.
[29] Dimitrios Georgakopoulos,et al. The pathogenesis of familial hypertrophic cardiomyopathy: Early and evolving effects from an α-cardiac myosin heavy chain missense mutation , 1999, Nature Medicine.
[30] F. Epstein,et al. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. , 1991, The New England journal of medicine.
[31] T. Hewett,et al. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.
[32] Tak W. Mak,et al. Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum , 1998, Nature.
[33] R Hetzer,et al. Identification and expression of delta-isoforms of the multifunctional Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human myocardium. , 1999, Circulation research.
[34] E. Olson,et al. Cardiac hypertrophy: sorting out the circuitry. , 1999, Current opinion in genetics & development.
[35] Christine E. Seidman,et al. α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere , 1994, Cell.
[36] E. Erdmann,et al. Calcium content of the sarcoplasmic reticulum in isolated ventricular myocytes from patients with terminal heart failure. , 1998, Journal of molecular and cellular cardiology.
[37] Eric P. Hoffman,et al. Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.
[38] T. Tsukahara,et al. Emerin deficiency at the nuclear membrane in patients with Emery-Dreif uss muscular dystrophy , 1996, Nature Genetics.
[39] T. Chatila,et al. Calcium-dependent activation of TNF family gene expression by Ca2+/calmodulin kinase type IV/Gr and calcineurin. , 1999, Journal of immunology.
[40] L. Leinwand,et al. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. , 1994, The Journal of biological chemistry.
[41] G. Crabtree. Generic Signals and Specific Outcomes Signaling through Ca2+, Calcineurin, and NF-AT , 1999, Cell.
[42] A. Lin,et al. Opposing Effects of Jun Kinase and p38 Mitogen-Activated Protein Kinases on Cardiomyocyte Hypertrophy , 1998, Molecular and Cellular Biology.
[43] H Niimura,et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.
[44] A. Clerk,et al. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. , 1998, Circulation research.
[45] Anne J. Ridley,et al. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling , 1992, Cell.
[46] Michael J. Grusby,et al. The transcription factor NF-ATc is essential for cardiac valve formation , 1998, Nature.
[47] T. Hewett,et al. In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. , 1999, Circulation research.
[48] C. Aoki,et al. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. , 1992, The Journal of biological chemistry.
[49] P. Sassone-Corsi,et al. Signaling routes to CREM and CREB: plasticity in transcriptional activation. , 1999, Trends in biochemical sciences.
[50] Q. Li,et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. , 1997, The Journal of clinical investigation.
[51] Lewis C Cantley,et al. PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.
[52] S. Green,et al. Role of βARK in Long-Term Agonist-Promoted Desensitisation of the β2-Adrenergic Receptor , 1998 .
[53] J. Towbin,et al. Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. , 1995, Circulation.
[54] S. Murray,et al. Involvement of multiple cis elements in basal- and alpha-adrenergic agonist-inducible atrial natriuretic factor transcription. Roles for serum response elements and an SP-1-like element. , 1995, Circulation research.
[55] J. Sadoshima,et al. Angiotensin II and Other Hypertrophic Stimuli Mediated by G Protein–Coupled Receptors Activate Tyrosine Kinase, Mitogen-Activated Protein Kinase, and 90-kD S6 Kinase in Cardiac Myocytes The Critical Role of Ca2+-Dependent Signaling , 1995 .
[56] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.
[57] J. Molkentin,et al. Calcineurin and human heart failure , 1999, Nature Medicine.
[58] M. Caron,et al. Beta-adrenergic receptor kinase: primary structure delineates a multigene family. , 1989, Science.
[59] P. Parker,et al. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. , 1994, The Journal of biological chemistry.
[60] H. Erdjument-Bromage,et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). , 1992, The Journal of biological chemistry.
[61] F. Spinale,et al. The structure and function of the cardiac myocyte: a review of fundamental concepts. , 1999, The Journal of thoracic and cardiovascular surgery.
[62] A. Clerk,et al. Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. , 1997, Cellular signalling.
[63] J. Guerrero,et al. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. , 1999, The Journal of clinical investigation.
[64] G. Hasenfuss,et al. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. , 1995, Circulation.
[65] S. Snyder,et al. Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux , 1995, Cell.
[66] M. Cobb,et al. Mitogen-activated protein kinase pathways. , 1997, Current opinion in cell biology.
[67] Y. Hayashizaki,et al. Identification of the Syrian hamster cardiomyopathy gene. , 1997, Human molecular genetics.
[68] K. Chien,et al. Phorbol esters induce immediate-early genes and activate cardiac gene transcription in neonatal rat myocardial cells. , 1990, Journal of molecular and cellular cardiology.
[69] R. Ferrari,et al. The role of TNF in cardiovascular disease. , 1999, Pharmacological research.
[70] A. Clerk,et al. Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by the G-protein-coupled receptor agonist phenylephrine in the perfused rat heart. , 1998, The Biochemical journal.
[71] J. Frost,et al. Mitogen-activated protein kinases mediate changes in gene expression, but not cytoskeletal organization associated with cardiac muscle cell hypertrophy , 1994, The Journal of cell biology.
[72] P. Simpson,et al. Differential acute and chronic response of protein kinase C in cultured neonatal rat heart myocytes to alpha 1-adrenergic and phorbol ester stimulation. , 1988, Journal of molecular and cellular cardiology.
[73] E. A. O'neill,et al. T cell responses in calcineurin A alpha-deficient mice , 1996, The Journal of experimental medicine.
[74] R. Schwinger,et al. Reduced Ca2+-Sensitivity of SERCA 2a in Failing Human Myocardium due to Reduced Serin-16 Phospholamban Phoshorylation , 1999 .
[75] G. M. Briggs,et al. Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. , 1991, The Journal of clinical investigation.
[76] P. Simpson. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. , 1983, The Journal of clinical investigation.
[77] R. Lefkowitz,et al. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. , 1998, Science.
[78] M. Takemura,et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. , 1997, Journal of the American College of Cardiology.
[79] M. Böhm,et al. Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. , 1994, Circulation research.
[80] E. Olson,et al. GATA4: a novel transcriptional regulator of cardiac hypertrophy? , 1997, Circulation.
[81] E. Maestrini,et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy , 1994, Nature Genetics.
[82] H. Schulman,et al. Identification and characterization of δB-CaM kinase and δC-CaM kinase from rat heart, two new multifunctional Ca2+/calmodulin-dependent protein kinase isoforms , 1994 .
[83] A. Thorburn,et al. A Low-Affinity Serum Response Element Allows Other Transcription Factors To Activate Inducible Gene Expression in Cardiac Myocytes , 1999, Molecular and Cellular Biology.
[84] J Ross,et al. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. , 1999, The Journal of clinical investigation.
[85] Jiahuai Han,et al. The p38 MAP kinase pathway and its biological function. , 1998, Trends in cardiovascular medicine.
[86] John W. Adams,et al. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[87] J. Towbin,et al. Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23. , 1996, The Journal of clinical investigation.
[88] K. Chien,et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. , 1990, The Journal of biological chemistry.
[89] A. Clerk,et al. Cellular mechanisms of cardiac hypertrophy , 1998, Journal of Molecular Medicine.
[90] I. Rayment,et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle , 1996, Nature Genetics.
[91] L. Karns,et al. M-CAT, CArG, and Sp1 elements are required for alpha 1-adrenergic induction of the skeletal alpha-actin promoter during cardiac myocyte hypertrophy. Transcriptional enhancer factor-1 and protein kinase C as conserved transducers of the fetal program in cardiac growth. , 1995, The Journal of biological chemistry.
[92] A. Harding. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. , 1981, Brain : a journal of neurology.
[93] Jiahuai Han,et al. Cardiac Hypertrophy Induced by Mitogen-activated Protein Kinase Kinase 7, a Specific Activator for c-Jun NH2-terminal Kinase in Ventricular Muscle Cells* , 1998, The Journal of Biological Chemistry.
[94] I. Masuda,et al. A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. , 1999, Journal of hypertension.
[95] D. Leroith,et al. Insulin-like Growth Factor 1 Inhibits Apoptosis Using the Phosphatidylinositol 3′-Kinase and Mitogen-activated Protein Kinase Pathways* , 1997, The Journal of Biological Chemistry.
[96] J. Towbin,et al. X‐Linked Dilated Cardiomyopathy Molecular Genetic Evidence of Linkage to the Duchenne Muscular Dystrophy (Dystrophin) Gene at the Xp21 Locus , 1993, Circulation.
[97] J. Brown,et al. Dissociation of p44 and p42 Mitogen-activated Protein Kinase Activation from Receptor-induced Hypertrophy in Neonatal Rat Ventricular Myocytes (*) , 1996, The Journal of Biological Chemistry.
[98] A. Kong,et al. A gene defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p1–1q1 , 1994, Nature Genetics.
[99] P. Allen,et al. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. , 1992, Circulation research.
[100] S. Vatner,et al. Effects of chronic beta-adrenergic receptor stimulation in mice. , 1997, Journal of molecular and cellular cardiology.
[101] F. Muntoni,et al. Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. , 1993, The New England journal of medicine.
[102] L. Fananapazir,et al. Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. , 1995, The Journal of clinical investigation.
[103] Mark A Sussman,et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. , 1998, Science.
[104] S. Houser,et al. Cellular basis of contractile derangements of hypertrophied feline ventricular myocytes. , 1997, Journal of molecular and cellular cardiology.
[105] T. Borg,et al. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. , 1999, Circulation research.
[106] W. Schmitz,et al. Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. , 1999, Cardiovascular research.
[107] Y. Yazaki,et al. Mechanical stretch activates the stress‐activated protein kinase in cardiac myocytes , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[108] D. Levy,et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.
[109] R. Prywes,et al. p38 Mitogen-activated Protein Kinase Mediates the Transcriptional Induction of the Atrial Natriuretic Factor Gene through a Serum Response Element , 1998, The Journal of Biological Chemistry.
[110] A. Børglum,et al. α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy , 1999 .
[111] S. Ogawa,et al. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. , 1999, Circulation research.
[112] Y. Goto,et al. A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). , 1991, Biochimica et biophysica acta.
[113] E. Hoffman,et al. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations , 1999, Muscle & nerve.
[114] G. Dorn,et al. Sustained in vivo cardiac protection by a rationally designed peptide that causes ɛ protein kinase C translocation , 1999 .
[115] F. Muntoni,et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy , 1999, Nature Genetics.
[116] R. Lang,et al. Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. , 1998, The Journal of clinical investigation.
[117] C A Beltrami,et al. Apoptosis in the failing human heart. , 1997, The New England journal of medicine.
[118] W. Lederer,et al. Sarcoplasmic reticulum in heart failure: central player or bystander? , 1998, Cardiovascular research.
[119] P. Hogan,et al. Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.
[120] Y. Zou,et al. Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. , 1997, Circulation research.
[121] H. Youn,et al. Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. , 1998, Immunity.
[122] K. Chien,et al. Rho Is Required for Gαq and α1-Adrenergic Receptor Signaling in Cardiomyocytes , 1996, The Journal of Biological Chemistry.
[123] G. Danieli,et al. A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42-q43. , 1995, Human molecular genetics.
[124] C. Hall,et al. Regulation of Phosphorylation Pathways by p21 GTPases , 1996 .
[125] A. Thorburn. Ras activity is required for phenylephrine-induced activation of mitogen-activated protein kinase in cardiac muscle cells. , 1994, Biochemical and biophysical research communications.
[126] Y. Murakami,et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[127] John Calvin Reed,et al. Bcl‐2, Raf‐1 and mitochondrial regulation of apoptosis , 1998, BioFactors.
[128] H. Katus,et al. Frequency and phenotypes of familial dilated cardiomyopathy. , 1998, Journal of the American College of Cardiology.
[129] J A Osborne,et al. Familial dilated cardiomyopathy locus maps to chromosome 2q31. , 1999, Circulation.
[130] L. Goatley,et al. A viral mechanism for inhibition of the cellular phosphatase calcineurin. , 1998, Science.
[131] M. Martone,et al. Chronic Phospholamban–Sarcoplasmic Reticulum Calcium ATPase Interaction Is the Critical Calcium Cycling Defect in Dilated Cardiomyopathy , 1999, Cell.
[132] E. Olson,et al. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. , 1999, Circulation research.
[133] G. Danieli,et al. ARVD4, a new locus for arrhythmogenic right ventricular cardiomyopathy, maps to chromosome 2 long arm. , 1997, Genomics.
[134] S. R. Datta,et al. Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.
[135] M. Caron,et al. Beta-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[136] L. Leinwand,et al. Identification of a cis-acting regulatory element conferring inducibility of the atrial natriuretic factor gene in acute pressure overload. , 1997, The Journal of clinical investigation.
[137] K. Chien,et al. The Low Molecular Weight GTPase Rho Regulates Myofibril Formation and Organization in Neonatal Rat Ventricular Myocytes , 1998, The Journal of Biological Chemistry.
[138] K. Campbell,et al. The sarcoglycan complex in limb-girdle muscular dystrophy. , 1998, Current opinion in neurology.
[139] N. Ahn,et al. Inhibition of a signaling pathway in cardiac muscle cells by active mitogen-activated protein kinase kinase. , 1995, Molecular biology of the cell.
[140] J. Heath,et al. Cardiotrophin-1 Activates a Distinct Form of Cardiac Muscle Cell Hypertrophy , 1996, The Journal of Biological Chemistry.
[141] R. Hajjar,et al. Effect of protein kinase C activation on sarcoplasmic reticulum function and apparent myofibrillar Ca2+ sensitivity in intact and skinned muscles from normal and diseased human myocardium. , 1990, Circulation research.
[142] T. Chatila,et al. Cyclosporin A‐sensitive induction of the Epstein‐Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member , 1997, The EMBO journal.
[143] F. Baas,et al. Mapping of the locus for X-linked cardioskeletal myopathy with neutropenia and abnormal mitochondria (Barth syndrome) to Xq28. , 1991, American journal of human genetics.
[144] J. Seidman,et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.
[145] E. Neer,et al. Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[146] E. Homsher,et al. Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. , 1996, The Journal of clinical investigation.
[147] L. Leinwand,et al. Mice Expressing Mutant Myosin Heavy Chains Are a Model for Familial Hypertrophic Cardiomyopathy , 1996, Molecular medicine.
[148] T. Doetschman,et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. , 1994, Circulation research.
[149] T. McIntosh,et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. , 1998, The Journal of clinical investigation.
[150] F. Giordano,et al. Antisense fosB RNA inhibits thrombin-induced hypertrophy in cultured pulmonary arterial smooth muscle cells. , 1998, Circulation.
[151] Richard Treisman,et al. Signal-Regulated Activation of Serum Response Factor Is Mediated by Changes in Actin Dynamics , 1999, Cell.
[152] R. Venema,et al. Protein kinase C-mediated phosphorylation of troponin I and C-protein in isolated myocardial cells is associated with inhibition of myofibrillar actomyosin MgATPase. , 1993, The Journal of biological chemistry.
[153] A. Nogami,et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. , 1993, The Journal of clinical investigation.
[154] H. Schunkert. Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease , 1997, Journal of Molecular Medicine.
[155] T. Rebbeck,et al. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. , 1999, Circulation.
[156] M. Rudnicki,et al. Severe cardiomyopathy in mice lacking dystrophin and MyoD. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[157] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[158] D. Mann,et al. Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .
[159] H. Watkins,et al. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[160] Y. Fujio,et al. Novel missense mutation in cardiac troponin T gene found in Japanese patient with hypertrophic cardiomyopathy. , 1997, Journal of molecular and cellular cardiology.
[161] J. Beckmann,et al. Cardiac myosin binding protein–C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy , 1995, Nature Genetics.
[162] P. Sugden,et al. Signaling in myocardial hypertrophy: life after calcineurin? , 1999, Circulation research.
[163] K. Chien,et al. Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. , 1996, Development.
[164] W. Koch,et al. Mechanism of β-Adrenergic Receptor Desensitization in Cardiac Hypertrophy Is Increased β-Adrenergic Receptor Kinase* , 1997, The Journal of Biological Chemistry.
[165] A. Thorburn,et al. MAP kinase‐ and Rho‐dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells , 1997, The EMBO journal.
[166] R. Frank,et al. Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. , 1996, The New England journal of medicine.
[167] F. McCormick,et al. A role for Rho in Ras transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[168] A. Tajik,et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. , 1992, The New England journal of medicine.
[169] H. Schulman,et al. The multifunctional calcium/calmodulin-dependent protein kinase: from form to function. , 1995, Annual review of physiology.
[170] H. Kung,et al. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells , 1998, Nature.
[171] J. Seidman,et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. , 1999, The New England journal of medicine.
[172] D. Kass,et al. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. , 1999, The Journal of clinical investigation.
[173] Anthony J. Muslin,et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. , 1999, The Journal of clinical investigation.
[174] L. Kunkel,et al. Mutations in the Dystrophin-Associated Protein γ-Sarcoglycan in Chromosome 13 Muscular Dystrophy , 1995, Science.
[175] Hao Ren,et al. Regulation of the Calmodulin-stimulated Protein Phosphatase, Calcineurin* , 1998, The Journal of Biological Chemistry.
[176] H. Watkins,et al. Sudden death due to troponin T mutations. , 1997, Journal of the American College of Cardiology.
[177] Hammond Hk,et al. Beta-adrenergic receptors and receptor signaling in heart failure. , 1999 .
[178] S. Snyder,et al. Cain, A Novel Physiologic Protein Inhibitor of Calcineurin* , 1998, The Journal of Biological Chemistry.
[179] D. Zechner,et al. A Role for the p38 Mitogen-activated Protein Kinase Pathway in Myocardial Cell Growth, Sarcomeric Organization, and Cardiac-specific Gene Expression , 1997, The Journal of cell biology.
[180] C. Marshall,et al. Hypertrophic Agonists Stimulate the Activities of the Protein Kinases c-Raf and A-Raf in Cultured Ventricular Myocytes (*) , 1995, The Journal of Biological Chemistry.
[181] A. Hata,et al. Angiotensinogen gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. , 1997, American heart journal.
[182] V. Fuster,et al. The natural history of idiopathic dilated cardiomyopathy. , 1981, The American journal of cardiology.
[183] D C Harrison,et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.
[184] M. Keating,et al. Mapping a cardiomyopathy locus to chromosome 3p22-p25. , 1996, The Journal of clinical investigation.
[185] J C Reed,et al. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. , 1999, Science.
[186] S. Humphries,et al. Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy. , 1995, Journal of the American College of Cardiology.
[187] P. Sugden,et al. Endothelin‐1, phorbol esters and phenylephrine stimulate MAP kinase activities in ventricular cardiomyocytes , 1993, FEBS letters.
[188] P. Simpson. β-Protein Kinase C and Hypertrophic Signaling in Human Heart Failure , 1999 .
[189] S. Powers,et al. HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. , 1993, The Journal of biological chemistry.
[190] P. Sugden,et al. The Mitogen-activated Protein Kinase Kinase MEK1 Stimulates a Pattern of Gene Expression Typical of the Hypertrophic Phenotype in Rat Ventricular Cardiomyocytes (*) , 1995, The Journal of Biological Chemistry.
[191] Y. Zou,et al. Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. , 1999, Circulation research.
[192] M. Yaffe,et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. , 1999, Science.
[193] J. Lorenz,et al. Abnormal Cardiac Structure and Function in Mice Expressing Nonphosphorylatable Cardiac Regulatory Myosin Light Chain 2* , 1999, The Journal of Biological Chemistry.
[194] A. Clerk,et al. Stimulation of phosphatidylinositol hydrolysis, protein kinase C translocation, and mitogen-activated protein kinase activity by bradykinin in rat ventricular myocytes: dissociation from the hypertrophic response. , 1996, The Biochemical journal.
[195] H. Singer,et al. Identification of novel isoforms of the delta subunit of Ca2+/calmodulin-dependent protein kinase II. Differential expression in rat brain and aorta. , 1993, The Journal of biological chemistry.
[196] M. Komajda,et al. Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes. , 1998, European heart journal.
[197] M. Martone,et al. Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy , 1999, Nature Medicine.
[198] L. Mestroni,et al. A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart. , 1995, The Journal of clinical investigation.
[199] L. Mestroni,et al. A new locus for arrhythmogenic right ventricular dysplasia on the long arm of chromosome 14. , 1996, Genomics.
[200] D. Wallace,et al. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNALys mutation , 1990, Cell.
[201] K. Sliwa,et al. Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy. , 1999, The American journal of cardiology.
[202] M. Yacoub,et al. Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. , 1996, Circulation.
[203] K. Mikoshiba,et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. , 1995, Circulation.
[204] B. Pitt,et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. , 1986, American heart journal.
[205] A. Koretsky,et al. Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .
[206] K. Chien,et al. Cardiotrophin 1 (CT-1) Inhibition of Cardiac Myocyte Apoptosis via a Mitogen-activated Protein Kinase-dependent Pathway , 1997, The Journal of Biological Chemistry.
[207] W. Lederer,et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. , 1997, Science.
[208] R. Hajjar,et al. Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. , 1998, The Journal of clinical investigation.
[209] A. Clerk,et al. Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. , 1996, The Biochemical journal.
[210] J. Towbin,et al. The role of cytoskeletal proteins in cardiomyopathies. , 1998, Current opinion in cell biology.
[211] G. Pavlath,et al. Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells. , 1998, Molecular biology of the cell.
[212] P. Warne,et al. Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras , 1997, Cell.
[213] Pascale Richard,et al. Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy , 1998, Journal of Molecular Medicine.
[214] M. Murakami,et al. Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. , 1995, American heart journal.
[215] M. Davies,et al. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy , 1999, Heart.
[216] M. Koenig,et al. Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.
[217] M. Marcus,et al. The heart in hypertension. , 1992, The New England journal of medicine.
[218] J Ross,et al. Cardiac Muscle Cell Hypertrophy and Apoptosis Induced by Distinct Members of the p38 Mitogen-activated Protein Kinase Family* , 1998, The Journal of Biological Chemistry.
[219] M. Komajda,et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. , 1997, Journal of molecular and cellular cardiology.
[220] K. Chien,et al. The MEKK-JNK Pathway Is Stimulated by α1-Adrenergic Receptor and Ras Activation and Is Associated with in Vitroand in Vivo Cardiac Hypertrophy* , 1997, The Journal of Biological Chemistry.
[221] M. Pericak-Vance,et al. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. , 1997, American journal of human genetics.
[222] J. Sanes,et al. ε-Sarcoglycan Replaces α-Sarcoglycan in Smooth Muscle to Form a Unique Dystrophin-Glycoprotein Complex* , 1999, The Journal of Biological Chemistry.
[223] J. Ross,et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[224] R. Brady,et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. , 1967, The New England journal of medicine.
[225] C. Widmann,et al. MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases? , 1997, Current opinion in genetics & development.
[226] S. Lehnart,et al. Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. , 1999, Circulation.
[227] H Fujisawa,et al. Tissue-specific expression of four types of rat calmodulin-dependent protein kinase II mRNAs. , 1989, The Journal of biological chemistry.
[228] L. Van Aelst,et al. Rho GTPases and signaling networks. , 1997, Genes & development.
[229] R. Lefkowitz,et al. Desensitization of G protein-coupled receptors. , 1996, Recent progress in hormone research.
[230] G. Boivin,et al. Molecular and Physiological Effects of Overexpressing Striated Muscle β-Tropomyosin in the Adult Murine Heart (*) , 1995, The Journal of Biological Chemistry.
[231] J. Seidman,et al. A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation , 1990, Cell.
[232] T. Toyofuku,et al. Molecular regulation of phospholamban function and expression. , 1998, Trends in cardiovascular medicine.
[233] A. Clerk,et al. Regulation of mitogen-activated protein kinase cascades in the heart. , 1998, Advances in enzyme regulation.
[234] P. Sugden,et al. Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. , 1996, Circulation research.
[235] Minoru Hongo,et al. MLP-Deficient Mice Exhibit a Disruption of Cardiac Cytoarchitectural Organization, Dilated Cardiomyopathy, and Heart Failure , 1997, Cell.
[236] H. Okamura,et al. Selective inhibition of NFAT activation by a peptide spanning the calcineurin targeting site of NFAT. , 1998, Molecular cell.
[237] M. Böhm,et al. Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. , 1995, Circulation.
[238] R. Kloner,et al. Intramyocardial injections and protection against myocardial ischemia. An attempt to examine the cardioprotective actions of adenosine. , 1996, Circulation.
[239] T. Kishimoto,et al. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[240] S. Donnelly,et al. Familial Hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. , 1994, The Journal of clinical investigation.
[241] G Thiene,et al. The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24. , 1994, Human molecular genetics.
[242] J. Ross,et al. Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.
[243] E. Olson,et al. Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype? , 1999, Circulation research.
[244] K. Tanaka,et al. A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. , 1998, The Journal of clinical investigation.
[245] R. Krams,et al. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. , 1998, Hypertension.
[246] W. MacLellan,et al. Death by design. Programmed cell death in cardiovascular biology and disease. , 1997, Circulation research.
[247] C. Marshall,et al. Regulation of Ras·GTP Loading and Ras-Raf Association in Neonatal Rat Ventricular Myocytes by G Protein-coupled Receptor Agonists and Phorbol Ester , 1999, The Journal of Biological Chemistry.
[248] Y. Ip,et al. Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. , 1998, Current opinion in cell biology.
[249] O. Ornatsky,et al. Immunolocalization of meta-vinculin in human smooth and cardiac muscles , 1988, The Journal of cell biology.
[250] M. Wilkinson,et al. SAPKs and transcription factors do the nucleocytoplasmic tango. , 1998, Genes & development.
[251] Y. Zou,et al. Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes. , 1995, The Journal of clinical investigation.
[252] M. Lopez-Ilasaca. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. , 1998, Biochemical pharmacology.
[253] R. Bonow,et al. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. , 1987, The American journal of cardiology.
[254] S. Houser,et al. Function of the cardiac myocyte in the conundrum of end-stage, dilated human heart failure. , 1999, Circulation.
[255] Jeffrey Robbins,et al. A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.
[256] G. Dorn,et al. Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice , 1999 .
[257] G. Dorn,et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice , 1997 .
[258] K. Chien,et al. Ventricular Expression of a MLC-2v-ras Fusion Gene Induces Cardiac Hypertrophy and Selective Diastolic Dysfunction in Transgenic Mice (*) , 1995, The Journal of Biological Chemistry.
[259] D. Mann,et al. Expression of a Mutation Causing Hypertrophic Cardiomyopathy Disrupts Sarcomere Assembly in Adult Feline Cardiac Myocytes , 1995 .
[260] M. B. Perryman,et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy , 1993, The Lancet.
[261] M. Matsuzaki,et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy , 1997, Nature Genetics.
[262] M. Patton,et al. Cardiologic Abnormalities in Noonan Syndrome: Phenotypic Diagnosis and Echocardiographic Assessment of 118 Patients , 1993, Journal of the American College of Cardiology.
[263] A. Clerk,et al. Stimulation of the p38 Mitogen-activated Protein Kinase Pathway in Neonatal Rat Ventricular Myocytes by the G Protein–coupled Receptor Agonists, Endothelin-1 and Phenylephrine: A Role in Cardiac Myocyte Hypertrophy? , 1998, The Journal of cell biology.
[264] B. Lowes,et al. Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin. , 1996, Circulation.
[265] S. Izumo,et al. Apoptosis: basic mechanisms and implications for cardiovascular disease. , 1998, Circulation research.
[266] L. Mestroni,et al. Linkage of familial dilated cardiomyopathy to chromosome 9. Heart Muscle Disease Study Group. , 1995, American journal of human genetics.
[267] K. Campbell,et al. Disruption of the Sarcoglycan–Sarcospan Complex in Vascular Smooth Muscle A Novel Mechanism for Cardiomyopathy and Muscular Dystrophy , 1999, Cell.
[268] D. DeMets,et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.